Alarming new study reveals overlooked factor that can lead to brain tumors: 'These findings point to a possible link'
Harmful gases can pose even more serious health concerns than respiratory problems. Researchers have found a link between exposure to ultrafine particles and aggressive brain tumors.
What's happening?
According to Euronews, a study by researchers from the Danish Cancer Institute indicates that long-term exposure to fine particulate matter, elemental carbon, nitrogen dioxide, and ultrafine particles contributes to the development of a common brain tumor.
"While research on the health effects of ultrafine particles is still in its early stages, these findings point to a possible link between traffic-related ultrafine particle exposure and the development of meningioma," said Ulla Hvidtfeldt, one of the authors of the study.
Though meningiomas are not typically cancerous, they cause neurological symptoms that impair brain function.
The findings echo earlier reports, such as one linking PM2.5 exposures to brain damage, cancer, and premature death, and another tying toxic airborne substances to higher dementia risk.
Why is this discovery important?
This research shows how polluting particles affect more than just our lungs — they can harm the brain too.
What makes this especially concerning is that these pollutants come from common sources such as traffic exhaust, smoke, and even ordinary household products, meaning regular, long-term exposure is more common than we realize.
Children, older adults, and low-income communities face the greatest risks because of long-term exposure and limited access to clean-air infrastructure.
Left unaddressed, this could translate into more cases of brain disease, rising health care costs, and irreversible neurological damage — all driven by an invisible yet largely preventable threat in the air we breathe.
What's being done about the issue?
While there are no findings that suggest cleaner air reduces the risk of brain tumors, improving air quality could still have public health benefits. That's why efforts to clean up the air, including advocacy within workplaces, are increasingly urgent.
Do you worry about the quality of the air inside your home?
Yes — often
Yes — but only sometimes
Only when it's bad outside
No — I never do
Click your choice to see results and speak your mind.
Governments around the world are taking steps to reduce air pollution.
Europe is pursuing an action plan to reach a 55% decrease in premature deaths caused by air pollution, per the European Environment Agency. In Asia, countries are implementing air quality monitoring solutions, as the Asia-Pacific Economic Cooperation reported.
Individuals can take local action and support community initiatives to improve air quality. People can also help reduce harmful gases in the air by choosing electric vehicles, using public transit, and installing solar panels at home.
As scientists continue to investigate the connection between air quality and brain health, this study serves as a crucial reminder: A cleaner environment isn't just better for the planet — it may also help protect our brains.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
10 minutes ago
- Washington Post
Bad diets, too many meds, no exercise: A look inside the latest 'Make America Healthy Again' report
WASHINGTON — A report that U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has promised will improve the health of America's children does not call on the government to make significant changes to its food or farming policies, according to a draft document obtained by The Associated Press. The 'Make America Healthy Again' strategy report is supposed to be one of Kennedy's signature achievements as the nation's health secretary, giving the government a roadmap to help its citizens lose weight, reduce chronic diseases and exercise more. Before coming to Washington, Kennedy had spent much of his career decrying the harms of chemicals sprayed on crops, prescription drugs, ultraprocessed foods, and vaccines. His coalition, then, has expected him to take bold action as the nation's top health leader. But a draft of the so-called 'MAHA' report, first reported by The New York Times Thursday night, mostly calls on the government to further study chronic diseases, bad air quality, Americans' diets and prescription drug use. The report lays out four problem areas – poor diet, chemical exposure, lack of physical activity and overuse of medications -- that are to blame for chronic diseases in the U.S. The White House has held off on publicly releasing the report, which was submitted to President Donald Trump on Tuesday. The latest report is the policy companion to a 'MAHA' report released in May, which was found to have several errors in it. White House spokesman Kush Desai refused to confirm whether the copy obtained by the Associated Press was a final version, though HHS officials have insisted the report has been finalized since Tuesday. 'President Trump pledged to Make America Healthy Again, and the Administration is committed to delivering on that pledge with Gold Standard Science,' Desai said. 'Until officially released by the White House and MAHA Commission, however, any documents purporting to be the second MAHA Report should be considered as nothing more than speculative literature.' Some in the agricultural industry had warily anticipated the report, fearing it would call for bans or investigations into the use of pesticides and herbicides that farmers in the U.S. regularly spray on crops to control weeds and enhance yields. Other farmers were concerned about how the report may target the use of corn syrup , a common sweetener, in American foods. Both products have been a central talking point in Kennedy's 'MAHA' movement, which has attracted a diverse coalition of suburban and rural moms, Trump supporters and liberals concerned about the nation's food supply. Instead, the report calls for an 'awareness' campaign to raise confidence in pesticides. Concerns from the agricultural industry waned as the report hit the president's desk, with one of Kennedy's closest advisers, Calley Means, calling for MAHA supporters to work with major farm companies on Tuesday. Means also acknowledged that the 'pace of political change' can be frustrating. 'We need to build bridges,' Means said, adding that: 'We are not going to win if the soybean farmers and the corn growers are our enemy.' Means did not respond to a request for comment on Friday. A spokesman for Kennedy also declined to comment. The report urges the National Institutes of Health – which is facing a 40% cut to its budget under the Trump administration – to undertake several studies on Americans' health, including research on vaccine injury, autism, air quality, water quality, prescription drugs, and nutrition. The report also calls for changes to the foods served in schools and hospitals, something that will be hard to deliver with the Trump administration's funding cuts, said Kari Hamerschlag, the deputy director of the food and agriculture at the nonprofit Friends of the Earth. Earlier this year, the Republican-led administration wiped out $1 billion set aside that helped food banks and schools procure food directly from local farmers. 'This is not going to transform our food and farming system,' Hamerschlag said. 'This is not going to make people healthier. They need to put resources behind their recommendations.' ___
Yahoo
23 minutes ago
- Yahoo
Researchers use 'acid bubbles' in game-changing method to create valuable materials: 'This is a major finding'
Researchers use 'acid bubbles' in game-changing method to create valuable materials: 'This is a major finding' While you likely hear about carbon dioxide in a negative way, it can be turned into useful things. And although the process isn't efficient, a team of researchers may have discovered a better way. According to Tech Xplore, carbon dioxide can be turned into alcohols, ethylene, or carbon monoxide using a method called electrochemical CO2 reduction, using electricity — preferably from renewable sources. It "can be further refined into fuels or used in industrial processes, potentially turning a major pollutant into a feedstock." Unfortunately, the process creates potassium bicarbonate salts, which clog up the gas flow channels. A team of researchers at Rice University has discovered that using acid-humidified CO2 instead of water is much more efficient. Tech Xplore wrote: "In tests using a silver catalyst — a common benchmark for converting CO2 to carbon monoxide — the system operated stably for over 2,000 hours in a lab-scale device and more than 4,500 hours in a 100-square-centimeter, scaled-up electrolyzer." In comparison, water-humidified CO2 failed after 80 hours due to salt buildup. Co-first author and Rice chemical and biomolecular engineering graduate student Ahmad Elgazzar said: "This is a major finding for CO2 electrolysis." The study was published in Science. Given that the planet has more carbon dioxide than nature can absorb, finding a way to turn the harmful gas into something useful is a great way to get rid of the excess gas. Carbon dioxide is one of the poisonous gases that are produced by dirty energy sources. These toxic gases contribute to the planet's warming, which is causing extreme weather events that also threaten the world's food crops. One way to combat poisonous gases is for society to reduce its reliance on dirty energy sources so that less toxic gas is released into the atmosphere. Do you worry about the quality of the air inside your home? Yes — often Yes — but only sometimes Only when it's bad outside No — I never do Click your choice to see results and speak your mind. In the meantime, projects like electrochemical CO2 reduction using acid bubbles are one way to help eliminate the toxic gas, and you can donate to climate causes that are doing this vital work. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
28 minutes ago
- Yahoo
3 ways the GLP-1 market has changed shape this year
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo Nordisk are doing all they can to secure their dominance. The two pharma giants recently revealed what they see as the emerging market opportunities, pitfalls and changing dynamics as they continue to compete head to head. Novo's sales rose 18% during the first half compared to the same period last year, but the Danish pharma lowered its revenue and profit outlook for the rest of 2025 due to slower-than-expected growth. Lilly, meanwhile, is taking over the space thanks to the popularity of Zepbound, its tirzepatide drug for obesity. The Indiana-based company reported that revenue rose 38% during the second quarter of the year, and 41% for the first half. Lilly also upped its 2025 guidance due to strong demand for its GLP-1 drugs. The quarterly results highlighted how the two companies are competing against each other as other drugmakers wait on the sidelines for their candidates to move through the clinic. Here's what the latest earnings reports from Lilly and Novo revealed about the evolving GLP-1 market. The market is growing Overall, the GLP-1 market grew in the second quarter, with Lilly's total prescriptions up 41% compared to the same period last year when prescriptions rose just 13%. According to Lilly, the company is taking up even more market share. After eclipsing Novo earlier this year when it secured 53% of the market, Lilly saw its share rise to 57% during the second quarter, according to an investor presentation. The company also said its tirzepatide meds now account for two-thirds of all patients taking obesity drugs. And executives see more upside in the future since only about 4% of Americans were taking a GLP-1 for obesity or diabetes last year. In particular, Lilly is bullish on Zepbound's potential to become the most widely used GLP-1 for obesity. 'While market growth continues to be robust, overall penetration into the addressable population is still low and we believe significantly more patients can benefit from incretin therapy,' Lucas Montarce, Lilly's CFO, said during the earnings call last week. Novo, meanwhile, was singing a different tune in its earnings report, noting that growth of its GLP-1 drugs for diabetes was slowing during the quarter compared to prior years. But with the obesity market expanding, there's still plenty of room to improve according to David Moore, president of Novo Nordisk and executive vice president of U.S. operations. 'The story continues to be about market expansion for obesity,' he said during the quarterly earnings call. The race for the pill is ramping up Both Novo and Lilly are in late-state trials for oral versions of their GLP-1 drugs, and Novo is already pursuing U.S. approval for its once-daily semaglutide pill. The FDA is expected to render a decision regarding the drug later this year. In conjunction with its quarterly earnings report, Lilly announced the latest results from a phase 3 trial of its oral GLP-1, orforglipron, revealing participants lost an average of 12.4% of their weight over 72 weeks. The pill didn't outperform Novo's Wegovy as analysts had hoped, sending Lilly's stock falling in the immediate aftermath of the news despite otherwise stellar earnings results. Still, the company is pushing forward with the pill and working toward regulatory submissions this year, with anticipated results from five trials for diabetes and obesity over the next five months. Lilly also plans to initiate late-stage studies for hypertension and knee osteoarthritis later this year. Even if it's not as effective as Novo's option, Lilly's pill could still appeal to patients. 'Orforglipron has the potential to be a more convenient alternative to injectable treatments and to be utilized to support early disease intervention in the primary care setting,' Lilly's chief scientific officer Dr. Daniel Skovronsky said during the earnings call. Both drugmakers are racing to bring their pill versions to market, and Novo may have an advantage as it looks to regain market share from Lilly. Novo is also looking to differentiate itself through combination therapies, both injectables and pill versions, in the hopes of improving results and reducing side effects. Manufacturing is getting more competitive With their GLP-1 products in high demand, Novo and Lilly have been ramping up manufacturing investments. Amid the threat of tariffs from President Donald Trump, Lilly has poured billions into domestic manufacturing. In February, the pharma giant said it was adding four new manufacturing sites in the U.S. And Novo has been shelling out hundreds of millions to increase manufacturing capacity globally since last year. Novo also closed its $16.5 billion acquisition of contract manufacturer Catalent last year, ensuring its U.S. production footprint would scale to meet demand for GLP-1 drugs. As both drugmakers pour fresh funds into building new facilities, U.S. regions are aiming to attract and retain the pharma giants. Wisconsin Governor Tony Evers offered $100 million in performance-based state tax credits to Eli Lilly last week in connection with the company's $4 billion facility expansion in the state. Lilly CEO David Ricks noted the company 'produced more than 1.6 times the amount of salable incretin doses during the first half of 2025 when compared to the first half of 2024,' thanks to new manufacturing capacity. Lilly also plans to announce two new sites for manufacturing facilities later this year, he said. Recommended Reading With compounders out of the way, Lilly and Novo go after each other Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
